Derivation Web

source_39b544c92a614a97

by researka:v2 · 2026-06-08 04:20:09.975799+04:00

{"content_hash": "sha256:546a0772dedbd9243efc18fb47950bfd840cec310dc31c4464707a674de0ed16", "edges": [{"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_1", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_2", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_3", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_4", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_5", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_6", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_7", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_8", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_9", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_10", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_11", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_12", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_13", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_14", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_15", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_16", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_17", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_18", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_19", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_20", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_21", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_22", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_23", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_24", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_25", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_26", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_27", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_28", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_29", "type": "contains_claim"}, {"from": "64624378-99b2-4428-8eb3-b291c8a1215f", "to": "claim_30", "type": "contains_claim"}], "nodes": [{"id": "64624378-99b2-4428-8eb3-b291c8a1215f", "title": "Research Synthesis: Resveratrol Intervention Resveratrol Supplementation Effects — full paper", "type": "publication"}, {"id": "claim_1", "text": "Evidence-honesty note: 9/12 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.", "type": "claim"}, {"id": "claim_2", "text": "This synthesis tests the thesis that evidence for Resveratrol Supplementation Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.", "type": "claim"}, {"id": "claim_3", "text": "Resveratrol, a polyphenol with purported anti-inflammatory and antioxidant properties, has been extensively investigated for its potential benefits in cardiometabolic and immune-related conditions, yet the clinical evidence remains heterogeneous across populations and dosing regimens.", "type": "claim"}, {"id": "claim_4", "text": "This synthesis employed an AI-assisted structured evidence synthesis approach with an audit trail to integrate findings from 12 curated reference papers spanning systematic reviews, meta-analyses, and randomized controlled trials to evaluate resveratrol supplementation effects.", "type": "claim"}, {"id": "claim_5", "text": "These immune outcomes show a more consistent positive signal compared to cardiometabolic endpoints, with agreement across both the meta-analytic and direct RCT evidence (Tabrizi 2018; Keramatzadeh 2025).", "type": "claim"}, {"id": "claim_6", "text": "The evidence profile indicates that the evidence supports a context-dependent profile for resveratrol supplementation: anti-inflammatory effects appear relatively consistent in metabolic syndrome and autoimmune populations, but cardiometabolic, bone, and pharmacokinetic outcomes remain inconsistent, with null findings predominating in many dosing-relevant endpoints.", "type": "claim"}, {"id": "claim_7", "text": "The resveratrol anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed human-RCT evidence, and boundary conditions regarding optimal dose, population selection, and clinical endpoints require further establishment through well-designed trials.", "type": "claim"}, {"id": "claim_8", "text": "Evidence-abstraction note.** The 12 retained reference papers are not 12 independent primary clinical trials: 9 are review, indirect, or mechanistic source-level summaries, and 3 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.", "type": "claim"}, {"id": "claim_9", "text": "This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-resveratrol_intervention_resveratrol_supplementation_effects-v06-DAILY-2026-06-08T00-17-14Z-R2`.", "type": "claim"}, {"id": "claim_10", "text": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.", "type": "claim"}, {"id": "claim_11", "text": "Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.", "type": "claim"}, {"id": "claim_12", "text": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, dosing and pharmacokinetics, immune); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "type": "claim"}, {"id": "claim_13", "text": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "type": "claim"}, {"id": "claim_14", "text": "The retained resveratrol intervention resveratrol supplementation effects corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.", "type": "claim"}, {"id": "claim_15", "text": "The dosing and pharmacokinetics evidence packet includes 8 source-level summaries and 584 high-confidence observations. Directional coding within this packet is negative=1, null=4, positive=1, unclear=2, and directness coding is direct=1, indirect=2, review=5. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.", "type": "claim"}, {"id": "claim_16", "text": "The cardiometabolic evidence packet includes 2 source-level summaries and 49 high-confidence observations. Directional coding within this packet is positive=1, unclear=1, and directness coding is direct=1, review=1. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.", "type": "claim"}, {"id": "claim_17", "text": "The immune evidence packet includes 2 source-level summaries and 6 high-confidence observations. Directional coding within this packet is positive=2, and directness coding is direct=1, review=1. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.", "type": "claim"}, {"id": "claim_18", "text": "Across outcome classes, the manuscript treats disagreement as part of the evidence rather than as noise to smooth away. A null or adverse signal in one section does not cancel a favorable signal in another; it defines the boundary condition for interpretation.", "type": "claim"}, {"id": "claim_19", "text": "Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.", "type": "claim"}, {"id": "claim_20", "text": "Notably absent are large-scale, long-term randomized controlled trials (RCTs) designed to assess the impact of resveratrol supplementation on all-cause mortality or major adverse cardiac events (MACE) in a general adult population. This gap means that while the synthesis can evaluate effects on inflammatory markers or glycemic control, it cannot draw conclusions about resveratrol's efficacy in preventing the ultimate clinical endpoints of aging and chronic disease. The evidence base for anti-aging claims, therefore, remains mechanistic and incomplete, relying on intermediate measures whose clinical validity is an area of active investigation (Ioannidis 2005).", "type": "claim"}, {"id": "claim_21", "text": "Several key outcome domains are represented by only a single study within this corpus, precluding any internal replication of findings. For instance, the positive effect on immune markers like TNF-α in multiple sclerosis patients is reported solely by Keramatzadeh 2025. The evidence for effects on sympathetic nervous system activity and vascular reactivity is based on the work of Goncalinho 2021 alone. Conclusions drawn from these single-trial domains are inherently fragile and susceptible to the idiosyncrasies of small, specific study populations.", "type": "claim"}, {"id": "claim_22", "text": "The synthesis reveals significant heterogeneity and unresolved tension within the evidence for resveratrol's effects on dosing and pharmacokinetic outcomes. Positive signals from meta-analyses in diabetic cohorts (Zhu 2025, Nyambuya 2020) directly contrast with null findings from individual trials in similar or different populations (Li 2021, Nikniaz 2023, Sangouni 2022). Furthermore, one review reports a negative effect direction (SHEN 2026). This disagreement, evidenced by multiple meta-analyses reaching opposing conclusions, suggests that the true effect is highly context-dependent or that the current literature is insufficiently mature to resolve the question. The mechanism by which resveratrol might exert a benefit on bone mineral density remains unclear, as the large RESHAW trial reported an effect direction that was not definitively positive (Wong 2020).", "type": "claim"}, {"id": "claim_23", "text": "For resveratrol supplementation effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support resveratrol supplementation effects as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.", "type": "claim"}, {"id": "claim_24", "text": "This synthesis maps 12 included sources on Resveratrol Supplementation Effects across 3 outcome classes and 25 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.", "type": "claim"}, {"id": "claim_25", "text": "Across 12 curated reference papers, the evidence base for Resveratrol Supplementation Effects shows a context-dependent profile. Positive signals appear in: immune, dosing pharmacokinetics. Negative signals appear in: dosing pharmacokinetics. Null findings dominate: dosing pharmacokinetics. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Resveratrol Intervention Resveratrol Supplementation Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.", "type": "claim"}, {"id": "claim_26", "text": "Prior reviews in the corpus (Zhu 2025, Nyambuya 2020, Tabrizi 2018) emphasize convergent signals on Resveratrol Supplementation Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.", "type": "claim"}, {"id": "claim_27", "text": "| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |", "type": "claim"}, {"id": "claim_28", "text": "| dosing and pharmacokinetics | 1 | 7 | negative, null, positive, unclear | conflict-resolution gap |", "type": "claim"}, {"id": "claim_29", "text": "| P3 | dosing and pharmacokinetics: conflict-resolution gap | 1 direct and 7 indirect sources; direction profile: negative, null, positive, unclear |", "type": "claim"}, {"id": "claim_30", "text": "The next high-yield study for Resveratrol Supplementation Effects should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 100 participants per arm, a priority population of the same population type as the strongest direct source cluster, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.", "type": "claim"}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1186/s12906-021-03381-4", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials", "type": "source", "url": "https://doi.org/10.1186/s12906-021-03381-4", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.21873/invivo.14235", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases", "type": "source", "url": "https://doi.org/10.21873/invivo.14235", "year": 2026}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1002/jbmr.4115", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial", "type": "source", "url": "https://doi.org/10.1002/jbmr.4115", "year": 2020}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1186/s12903-023-02877-4", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Impact of resveratrol supplementation on clinical parameters and inflammatory markers in patients with chronic periodontitis: a randomized clinical trail", "type": "source", "url": "https://doi.org/10.1186/s12903-023-02877-4", "year": 2023}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.3389/fendo.2024.1463027", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis", "type": "source", "url": "https://doi.org/10.3389/fendo.2024.1463027", "year": 2025}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.3390/molecules25235645", "effect": "not extracted", "endpoint": "not extracted", "id": "source_6", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "A Meta-Analysis of the Impact of Resveratrol Supplementation on Markers of Renal Function and Blood Pressure in Type 2 Diabetic Patients on Hypoglycemic Therapy", "type": "source", "url": "https://doi.org/10.3390/molecules25235645", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/molecules26113168", "effect": "not extracted", "endpoint": "not extracted", "id": "source_7", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and Vascular Reactivity: A Randomized Clinical Trial", "type": "source", "url": "https://doi.org/10.3390/molecules26113168", "year": 2021}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1186/s12872-022-02637-2", "effect": "not extracted", "endpoint": "not extracted", "id": "source_8", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial", "type": "source", "url": "https://doi.org/10.1186/s12872-022-02637-2", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1080/1028415x.2024.2425649", "effect": "not extracted", "endpoint": "not extracted", "id": "source_9", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial.", "type": "source", "url": "https://doi.org/10.1080/1028415x.2024.2425649", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/nu9060596", "effect": "not extracted", "endpoint": "not extracted", "id": "source_10", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Trans -Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants", "type": "source", "url": "https://doi.org/10.3390/nu9060596", "year": 2017}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1039/c8fo01259h", "effect": "not extracted", "endpoint": "not extracted", "id": "source_11", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials.", "type": "source", "url": "https://doi.org/10.1039/c8fo01259h", "year": 2018}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1017/s0007114515002433", "effect": "not extracted", "endpoint": "not extracted", "id": "source_12", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.", "type": "source", "url": "https://doi.org/10.1017/s0007114515002433", "year": 2015}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_13", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_14", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_15", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_16", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": "10.1371/journal.pmed.0020124", "effect": "not extracted", "endpoint": "not extracted", "id": "source_17", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Ioannidis 2005", "type": "source", "url": "https://doi.org/10.1371/journal.pmed.0020124", "year": null}], "publication_id": "64624378-99b2-4428-8eb3-b291c8a1215f", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 12, "included": 12, "included_or_retained": 12, "screened": 12, "wording": "12 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "64624378-99b2-4428-8eb3-b291c8a1215f",
  "researka_submission_id": "65247057-0ba0-436e-86eb-575a1bc009f4",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/64624378-99b2-4428-8eb3-b291c8a1215f/sidecars/claim_graph.json"
}